Mustang Bio (MBIO) Stock Price, News & Analysis

Company Overview

Mustang Bio, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas. On the rare disease front, Mustang Bio is developing gene therapy candidates aimed at lysosomal storage disorders and other inherited metabolic conditions, utilizing proprietary vector designs and manufacturing processes to deliver functional copies of deficient genes. Mustang Bio’s research collaborations and licensing agreements with leading academic institutions underpin its approach to translational science and clinical development.

Founded in 2015 and headquartered in Worcester, Massachusetts, Mustang Bio operates in North America and Europe, conducting multi‐center clinical studies to evaluate safety and efficacy of its product candidates. The company’s management team comprises industry veterans with expertise in cell therapy development, regulatory affairs and biomanufacturing. Through strategic partnerships and its own manufacturing capabilities, Mustang Bio seeks to advance first-in-class therapies from the laboratory to patients in need.

Key Stats

• Today's Range: $0.67 to $0.78
• 50-Day Range: $0.60 to $0.78
• 52-Week Range: $0.53 to $7.00
• Volume: 4.47 million shs
• Average Volume: 303,215 shs
• Market Capitalization: $5.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Mustang Bio Stock Analysis - MarketRank™

Mustang Bio scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Mustang Bio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Mustang Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mustang Bio is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mustang Bio is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mustang Bio has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.74% of the float of Mustang Bio has been sold short.

Short Interest Ratio / Days to Cover

Mustang Bio has a short interest ratio ("days to cover") of 1.31, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mustang Bio has recently decreased by 25.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mustang Bio does not currently pay a dividend.

Dividend Growth

Mustang Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mustang Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.00% of the stock of Mustang Bio is held by insiders.

Percentage Held by Institutions

9.95% of the stock of Mustang Bio is held by institutions.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 6/08/2026
• Next Earnings (Estimated): 8/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MBIO
• CIK: 1680048
• Web: www.mustangbio.com
• Phone: (781) 652-4500
• Fax: N/A
• Employees: 100
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -35.38%
• Return on Assets: -16.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.12
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 7,577,000
• Free Float: 7,274,000
• Market Cap: $5.08 million
• Optionable: Not Optionable
• Beta: 2.08